Randomized phase 2 study of investigational, selective aurora A kinase inhibitor alisertib (MLN8237) with weekly paclitaxel vs paclitaxel alone in patients (pts) with recurrent ovarian cancer (OC)
R. Coleman
Randomized phase 2 study of investigational, selective aurora A kinase inhibitor alisertib (MLN8237) with weekly paclitaxel vs paclitaxel alone in patients (pts) with recurrent ovarian cancer (OC)
R. Coleman